News

Main changes in the amended version of the Horizon Europe Research Infrastructures work programme

Published on | 1 year ago

Programmes
Research Infrastructures RI

The amended version of the Research Infrastructures work programme has been published on the European Commission Funding and Tenders Portal. The main changes concern the introduction of two new call topics under two existing destinations. Expected opening of the calls: 13 June 2024 and deadline: 19 September 2024.

  • Under destination Developing, consolidating and optimising the European research infrastructures landscape, maintaining global leadership (INFRADEV)
    • Call topic: HORIZON-INFRA-2024-DEV-02-01: Assessing the state of research infrastructures in Ukraine
  • Under destination Enabling an operational, open and fair EOSC ecosystem (INFRAEOSC)
    • Call topic: HORIZON-INFRA-2024-EOSC-02-01: Future Engagement Model for the EOSC Federation

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1829 articles available search in articles 

Testimonial

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.